Contract-Resource-Outsourcing-IndustryNews

  1. FDA Approves Ferring Pharmaceuticals' Degarelix (generic name) For Treatment Of Advanced Prostate Cancer 1/16/2009
    Ferring Pharmaceuticals, USA recently received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer.
  2. Kendle Expands Asia/Pacific Operations With Opening Of Additional Office In India 1/16/2009
    Kendle , a leading, global full-service clinical research organization, recently announced the opening of a second office in western India in the city of Ahmedabad, further expanding its presence in the country and executing on its plans for continued growth in the Asia/Pacific region.
  3. Endo Pharmaceuticals To Acquire Indevus Pharmaceuticals 1/7/2009
    Endo Pharmaceuticals and Indevus Pharmaceuticals, Inc. announced recently that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370M, or $4.50 per Indevus share, in cash, and up to an additional approximately $267M, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
  4. NanoInk Launches NanoStem Cell Division 1/6/2009
    NanoInk, Inc., a global leader in nanotechnology, began the new year by announcing the launch of its NanoStem Cell division.
  5. AstraZeneca And MAP Pharmaceuticals Announce Worldwide Collaboration To Develop And Commercialize Unit Dose Budesonide 12/22/2008
    AstraZeneca and MAP Pharmaceuticals, Inc. announced recently an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of budesonide.
  6. BioSpecifics Announces Partnership Between Pfizer And Auxilium For XIAFLEX™ In Europe 12/18/2008
    BioSpecifics Technologies Corp. , a biopharmaceutical company developing first in class collagenase based products, recently announced that its partner Auxilium Pharmaceuticals, Inc. has signed a license agreement with Pfizer, Inc. to market XIAFLEX (clostridial collagenase for injection) a first-in-class, late-stage biologic, in Europe and other territories for the treatment of Dupuytren's disease and Peyronie's disease.
  7. GE Healthcare Introduces ÄKTA™ready Liquid Chromatography System 12/16/2008
    GE Healthcare has launched ÄKTA™ready a liquid chromatography system designed for process scale-up and production for Phase I-III drug development and full scale production to GLP and cGMP standards.
  8. Medicago Announces Expansion Of Manufacturing Facility 12/16/2008
    Medicago Inc., recently announced it plans to invest $1.5M to expand its manufacturing facility located in the Technology Park of Quebec City to optimize manufacturing activities and provide additional space to produce clinical grade material for human clinical trials.
  9. Valeant To Acquire Dow Pharmaceutical Sciences, Inc. For $285M 12/11/2008
    Valeant Pharmaceuticals International recently announced that it has signed a definitive agreement to acquire Dow Pharmaceutical Sciences, Inc., a privately held dermatology company that specializes in the development of topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.
  10. Roche And FDA Agree On Pathway Towards U.S. Approval Of ACTEMRA® (tocilizumab) 12/5/2008
    Roche recently announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA® (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).